Why Avalyn Pharma Inc.’s (AVLN) Stock Is Down 5.62%
As of Tuesday, October 06, Avalyn Pharma Inc.’s AVLN share price has dipped by 5.62%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
Commentary & Analysis
Why Avalyn Pharma Inc.’s (AVLN) Stock Is Down 5.37%
As of Monday, October 05, Avalyn Pharma Inc.’s AVLN share price has dipped by 5.37%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Avalyn Pharma Inc.’s (AVLN) Stock Is Down 5.22%
As of Thursday, September 24, Avalyn Pharma Inc.’s AVLN share price has dipped by 5.22%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Avalyn Pharma Inc.’s (AVLN) Stock Is Down 5.55%
As of Wednesday, September 23, Avalyn Pharma Inc.’s AVLN share price has dipped by 5.55%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Avalyn Pharma Inc.’s (AVLN) Stock Is Down 5.50%
As of Tuesday, September 15, Avalyn Pharma Inc.’s AVLN share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | AVLN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,113.2 | $491.4 | 47% |
|
| Shares Out (Mil) | 29.7 | 42.7 | 37% |
|
| Institutional Ownership | na | 81.3% | na |
|
| Float (Mil) | 25.1 | 45.6 | 32% |
|
| Beta | na | 0.73 | na |
|
| Avg Daily Volume (000s) | 303 | 327 | 51% |
|
| Price Change (52-week) |
na | 56.8% | na |
|
| Growth | AVLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (2.4%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 1 | |
| Current EPS | ($0.750) | ($2.690) | ($2.580) | |
| Month Ago EPS | ($0.790) | ($1.940) | ($1.900) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.585) | ($1.940) | ($1.900) | |
| Year/Year Chg | (23.2%) | (96.9%) | (96.9%) | |
| Financials | AVLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($103) | ($11) | 11% |
|
| EPS (TTM) | ($12.338) | ($0.700) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($98) | ($7) | 6% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $16 | $6 | 31% |
|
| Enterprise Value (Q1) (Mil) | $1,001 | $493 | 41% |
|
| Valuation | AVLN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.79 | 2.15 | 65% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | AVLN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (48.6%) | (22.2%) | 12% |
|
| ROE | (51.9%) | (21.0%) | 15% |
|
| Liabilities to Assets | 6.4% | 32.3% | 3% |
|
| F-Score | 1 | 3 | na |
|
Avalyn Pharma Inc. did not pass any screens on 10/21/2026.
